Displaying all 2 publications

Abstract:
Sort:
  1. Vlahov D, Wang C, Ompad D, Fuller CM, Caceres W, Ouellet L, et al.
    Subst Use Misuse, 2008;43(3-4):413-28.
    PMID: 18365941 DOI: 10.1080/10826080701203013
    To quantify the risk of death among recent-onset (< 5 years) injection drug users, we enrolled 2089 injection drug users (IDUs) age
    Matched MeSH terms: Substance Abuse, Intravenous/mortality*
  2. Bruce RD, Govindasamy S, Sylla L, Haddad MS, Kamarulzaman A, Altice FL
    Am J Drug Alcohol Abuse, 2008;34(4):511-7.
    PMID: 18584580 DOI: 10.1080/00952990802122259
    Diversion of buprenorphine has been described in settings where it is legally prescribed and has become an increasing concern in Malaysia; it resulted in banning of buprenorphine in Singapore where unsubstantiated case reports suggested that buprenorphine injection was associated with particularly poor outcomes. We therefore conducted a case series of qualitative interviews with buprenorphine injectors in Kuala Lumpur, Malaysia to examine further the issues surrounding buprenorphine injection as well as the abuse of midazolam in combination with buprenorphine. Interviews with 19 men do not suggest significant adverse health consequences from buprenorphine injection alone and injectors have adapted diverted buprenorphine as a treatment modality. A subset of these injectors, however, combined buprenorphine and midazolam for euphoric effects with resultant symptoms of a possible pharmacological interaction. Prospective cohort studies, rather than hospital-derived samples, are needed to better understand the safety of buprenorphine injection.
    Matched MeSH terms: Substance Abuse, Intravenous/mortality*
Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links